Dec 17, 2024, 17:03 | Blog

Honored to participate in the inaugural Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer - Agenus

Agenus shared a post on LinkedIn: "We were honored to participate in the inaugural Global…

Dec 15, 2024, 11:51 | Blog

Dhan Chand: Honored to have presented at the Global Cancer Movement Conference

Dhan Chand, Vice President of Research at Agenus, reshared a post on LinkedIn by OncoDaily,…

Dec 14, 2024, 15:49 | Career

FairJourney Biologics has appointed Marc van Dijk as the new Chief Scientific Officer of Antibody Discovery and Engineering

FairJourney Biologics recently appointed Marc van Dijk as the new Chief Scientific Officer of Antibody…

Dec 13, 2024, 16:45 | Insight

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Agenus and Tanner Pharma announced a collaboration to provide expanded access to botensilimab (BOT) and…

Dec 10, 2024, 07:33 | Insight

Gevorg Tamamyan: 80 speakers and around 450 participants from 30 countries

Gevorg Tamamyan, Editor-in-chief of OncoDaily, shared a post on LinkedIn: “80 speakers and around 450…

Dec 1, 2024, 11:11 | Blog

Agenus supports the CRCCI in addressing critical gaps in Colorectal Cancer Care

Agenus reshared a post by Fight Colorectal Cancer on LinkedIn, adding: "Agenus is proud to…

Nov 22, 2024, 21:20 | Blog

Agenus joins Pancreatic Cancer Action Network in raising awareness

Agenus shared a post on LinkedIn: "Today is World Pancreatic Cancer Day and Agenus is…

Nov 17, 2024, 07:39 | Blog

Dhan Chand: Collaboration and innovation in cancer treatment at SITC 2024

Dhan Chand, Vice President of Research at Agenus, posted on LinkedIn: “Curing cancer requires more than innovative…

Nov 13, 2024, 15:07 | Blog

Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development

Agenus: Transforming Cancer Treatment with BOT/BAL While Strengthening Financial Foundations Agenus has announced its third-quarter…

Nov 9, 2024, 14:03 | Blog

OncoInfluencers to Follow on Social Media: Dr. Dhan Chand

We’re excited to feature Dr. Dhan Chand, a leader in cancer immunology and immunotherapy, as…

Nov 9, 2024, 10:50 | Blog

Dhan Chand: Excited to share our latest research at SITC2024

Dhan Chand, Vice President of Research at Agenus, posted on LinkedIn: "Excited to share our…

Nov 8, 2024, 12:37 | Positive

Jennifer Buell: Pioneering Leadership in Biotechnology

Dr. Jennifer Buell is a prominent figure in the biotechnology industry, currently serving as the…

Nov 7, 2024, 12:17 | Blog

Supporting Colorectal Cancer Alliance’s National Blue Hope Bash - Agenus

Agenus shared on LinkedIn: “This past weekend, Agenus was proud to support Colorectal Cancer Alliance’s…

Oct 29, 2024, 21:00 | Positive

Steven O'Day: At the Forefront of Immunotherapy

Dr. Steven O'Day, an immunotherapy pioneer and medical oncologist, is the Chief Medical Officer at…

Oct 25, 2024, 12:34 | Blog

Find out more about immunotherapy with Agenus

Agenus shared a post on LinkedIn: "Receiving a cancer diagnosis can be overwhelming and filled with…

Oct 23, 2024, 14:59 | Blog

Spotlight on Innovation: Dhan Chand, VP of Research at Agenus

Agenus shared on LinkedIn: “Meet Dhan Chand, our Vice President of Research. Dhan believes that…

Oct 22, 2024, 14:57 | Insight

Joseph Grossman: Botensilimab is effective against Tumors Poorly Responsive to Conventional Immunotherapy

Joseph Grossman, Vice President of Early Clinical Development at Agenus, shared a post on LinkedIn: "The…

Oct 19, 2024, 11:27 | Blog

Thank you, STAT, for another great summit! - Agenus

Agenus posted the following on LinkedIn: “Thank you, STAT, for another great summit! Our team…

Oct 17, 2024, 09:15 | Blog

Looking forward to Dr. Steven O'Day’s Eureka Moment talk at STAT Summit - Agenus

Agenus shared on LinkedIn: "Agenus has arrived at the STAT Summit! We’re looking forward to…

Oct 15, 2024, 11:59 | Blog

Celebrate 30 years of innovation with Agenus

Agenus shared on LinkedIn: "We’re on a mission to harness the power of the immune system to bring therapies…

Oct 7, 2024, 15:21 | Positive

Agenus CEO Dr. Garo Armen Honored with WITSA Eminent Person 2024 Award for Cancer Immunotherapy Breakthrough

Dr. Garo Armen, CEO and Chairman of Agenus Inc., Massachusetts-based leading immuno-oncology biotech, has been…

Oct 7, 2024, 06:49 | Blog

Agenus team at SITC’s 39th Annual Meeting in Houston

Agenus posted on LinkedIn: "We’ll be attending the Society for Immunotherapy of Cancer (SITC)’s 39th…

Oct 5, 2024, 15:31 | Insight

Advancing early detection and treatment: Agenus supports breast cancer awareness month

Agenus shared a post on LinkedIn: “The National Breast Cancer Foundation, Inc. reports that more…

Sep 27, 2024, 16:57 | Blog

Rethinking how we measure cancer immunotherapies at STAT Summit - Agenus

Agenus shared the following on LinkedIn: “We’re proud to sponsor this year’s STAT Summit, focused…

Sep 27, 2024, 12:14 | Blog

Proud to sponsor this year’s STAT Summit - Agenus

Agenus shared on LinkedIn: "We’re proud to sponsor this year’s STAT Summit, focused on delivering…

Sep 24, 2024, 16:52 | Blog

Assessment of the safety and efficacy of Balstilimab in combination with Botensilimab for NSCLC - Immune Oncology Research Institute

Immune Oncology Research Institute shared a post on LinkedIn: ''Assessment of the safety and efficacy…

Sep 20, 2024, 14:47 | Blog

That’s a wrap on ESMO2024 - Agenus

Agenus shared a post on LinkedIn: "That’s a wrap on ESMO2024. Our team had a great…

Sep 20, 2024, 11:44 | Blog

Angela V. Hafner promoted to Director of External Innovation at Agenus

Angela V. Hafner shared a post on LinkedIn: ''I’m happy to share that I’ve been…

Sep 15, 2024, 00:29 | Insight

Breelyn Wilky on botensilimab and balstilimab for refractory sarcomas at ESMO24

Agenus shared on LinkedIn: “Breelyn Wilky, presented new data at ESMO24 highlighting the potential of…

Sep 10, 2024, 13:38 | Insight

Agenus‘s latest data from the clinical trial of BOT/BAL in refractory sarcomas at ESMO24

Agenus shared on LinkedIn: “The Agenus team is headed to Barcelona for ESMO24. This Friday,…

Sep 5, 2024, 19:44 | Blog

A stage 4 young-onset cancer survivor speaks about the increase in colon cancer in young adults - Agenus

Agenus shared a post on LinkedIn: "Did you know, colorectal cancer has become the leading…

Sep 4, 2024, 11:47 | Dialogues

Dr. Benjamin Schlechter on Botensilimab: Practice-changing Drug | Most Promising Cancer Drugs 2024

In this episode of OncoDaily Interviews, Dr. Benjamin Schlechter, a distinguished medical oncologist at the…

Aug 29, 2024, 15:56 | Blog

Schedule a meeting with Agenus at ESMO24

Agenus shared on LinkedIn: "Attending ESMO24 in Barcelona from September 13-17? Our Medical Affairs team…

Aug 25, 2024, 20:10 | Blog

Urgent need for new therapies for colorectal cancer patients with MSS disease - Agenus

Agenus posted on LinkedIn: "Andrew Wortmann, Creative Director at Fight Colorectal Cancer, emphasizes the urgent…

Aug 10, 2024, 13:39 | Insight

Botensilimab’s effectiveness against tumours poorly responsive to conventional immunotherapy

Justin Stebbing shared a post on LinkedIn: “Congratulations to Dhan Chand and the Agenus team…

Aug 10, 2024, 11:58 | Insight

Botensilimab: A Revolutionary Fc-Enhanced CTLA-4 Inhibitor Transforming Cancer Immunotherapy

In the rapidly evolving landscape of oncology, we are witnessing remarkable advancements in various treatment…

Aug 9, 2024, 07:16 | Blog

Botensilimab’s mechanism of action and potential in addressing treatment-resistant cancers

Botensilimab is an investigational human Fc-enhanced CTLA-4 blocking antibody designed to boost both innate and…

Aug 7, 2024, 09:20 | Blog

Shushan Hovsepyan: Honored to interview Nils Eckardt

Shushan Hovsepyan shared a post by OncoDaily on LinkedIn, adding: ''I had the honor of…

Aug 2, 2024, 10:05 | Insight

Marianne Pearson about the urgent need for innovative treatment options for Colorectal cancer patients - Agenus

Agenus shared on LinkedIn: "Colorectal cancer is the second leading cause of cancer death in…

Aug 2, 2024, 08:47 | Dialogues

Driving Change in Oncology: the Vision of the Chief Medical Affairs Officer of Agenus

The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most…

Jul 31, 2024, 03:54 | Blog

What is Immunotherapy? - Agenus

Agenus posted on LinkedIn: "Curious about immunotherapy? Swipe to learn how this innovative treatment boosts…

Jul 29, 2024, 06:38 | Blog

Heart of a Warrior: Jennifer’s Triumphant Fight Against Cancer

Jennifer's story is a testament to strength and resilience. Faced with limited treatment options, she…

Jul 24, 2024, 08:09 | Blog

Gevorg Tamamyan: I urge Agenus to consider Armenia as the first country to register BOT/BAL combination

Gevorg Tamamyan shared on LinkedIn: "As I mentioned in my earlier post, we are ready in…

Jul 19, 2024, 02:00 | Blog

I ask Agenus to consider Armenia as the first country to register the BOT/BAL combination: Gevorg Tamamyan

"~20% ORR and 90% alive at 6 months in comparison to ZERO! How many patients…

Jul 18, 2024, 15:20 | Drugs

Our commitment to seek all possible pathways to make BOT/BAL available to patients is unwavering: Steven O'Day, Agenus CMO

Agenus shared on LinkedIn: "Today, we announced the outcomes of our End-of-Phase 2 meeting and…

Jul 13, 2024, 14:25 | OncoDaily Pulse

OncoDaily Magazine - Inaugural Issue

We are excited to announce that the Inaugural issue of OncoDaily Magazine was launched on…

Jul 13, 2024, 14:15 | Dialogues

I never knew how close to this disease I would eventually become - Benny Johnson’s personal story with cancer

The new issue of OncoDaily Magazine had the privilege to feature an exclusive interview with Dr.…

Jul 13, 2024, 09:41 | Insight

IMMONC - Immune Oncology Research Institute's Experience in Advancing Clinical Cancer Research in Armenia

Cancer affects people across the world regardless of their socioeconomic status. However, low- and middle-income…

Jul 12, 2024, 10:06 | Career

14 individuals recognized for their exceptional contributions in shaping the future of pharmaceutical communications

Fierce Life Sciences Events shared on LinkedIn: "Day 2 of the Pharma PR and Communications…

Jul 11, 2024, 18:15 | Positive

Alexa Buffa named one of 2024's Industry Rising Stars by Fierce Life Sciences Events

Agenus shared on LinkedIn: "Congratulations to our own Alexa Buffa on being named one of…

Jul 11, 2024, 13:16 | Blog

Steven O'Day about how immunotherapy stands apart from traditional chemotherapy - Agenus

Agenus shared a post on LinkedIn: . "Did you know immunotherapy activates the body’s own…

Jul 8, 2024, 12:29 | Drugs

Jennifer Buell: NCI Announces Availability of Botensilimab for Clinical Development

Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics, shared on X: “NCI Announces…

Jul 2, 2024, 09:22 | Societies

Inspired by engaging with the GI community at ESMOGI24 - Agenus

Agenus shared on LinkedIn: "That's a wrap on ESMOGI24! Our team was inspired by engaging…

Jul 2, 2024, 07:19 | Societies

25 Posts You Should Not Miss From ESMOGI24!

ESMOGI24 took place as an onsite event in Munich, Germany, from 26 to 29 June…

Jul 1, 2024, 16:15 | Blog

We need to hurry up, because cancer and patients cannot wait!

Gevorg Tamamyan, the Editor-in-chief of OncoDaily and CEO of Immune Oncology Research Institute, shared on…

Jul 1, 2024, 09:12 | Blog

Agenus - CTEP has announced the availability of botensilimab for clinical studies

Agenus shared on LinkedIn: “The National Cancer Institute (NCI)'s Cancer Therapy Evaluation Program (CTEP) has…

Jul 1, 2024, 02:25 | Blog

Insights from ESMOGI24 by Cathy Eng

ESMO GI 2024 took place from June 26 to 29 in Munich, Germany, featuring both…

Jun 28, 2024, 15:58 | Insight

Updates on BOT/BAL from ESMOGI24

ESMO GI 2024 is held in Munich, Germany, and online from June 26-29. Organized by…

Jun 28, 2024, 13:48 | Insight

Arndt Vogel: Neoadjuvant botensilimab + balstilimab in MSI and MSS CRC at ESMOGI24

Arndt Vogel shared on X: "Neoadjuvant botensilimab + balstilimab in MSI and MSS CRC at…

Jun 28, 2024, 13:41 | Insight

New data from the NEST clinical trial was presented at ESMOGI24 - Agenus

Agenus shared on their X page: "New data from the NEST clinical trial was presented…

Jun 28, 2024, 13:15 | Insight

The clinical utility of liquid biopsies detecting ctDNA in guiding treatment for patients with mCRC - ESMO

ESMO (European Society for Medical Oncology) shared on LinkedIn: "Data from two presentations at ESMOGI24…

Jun 28, 2024, 13:09 | Insight

Vittorio Studiale: Impressive pathological response rate with neoadjuvant BOT/BAL in MSS CRC

Vittorio Studiale, Medical Oncology Resident at University Hospital of Pisa, shared on X: "Impressive pathological…

Jun 28, 2024, 13:00 | Insight

Cathy Eng: Agenus with very promising data in early MSI-s/MSI-H colon cancer

Cathy Eng shared on X/Twitter: "Bot/Bal immunotherapy in colon cancer NEST 1/2. Agenus with very…

Jun 28, 2024, 11:27 | Societies

12 Posts You Should Not Miss From Day 2 of ESMOGI24!

ESMOGI24 is taking place as an onsite event in Munich, Germany, from 26 to 29 June 2024,…

Jun 27, 2024, 12:44 | Societies

Discuss the future of immuno-oncology with Agenus at ESMOGI24

Agenus shared on LinkedIn: "If you are a physician attending ESMOGI24 in Munich from June…

Jun 25, 2024, 15:51 | Career

Agenus Regulatory is hiring Director of Regulatory Affairs

Eric J. Olson, Global Head of Regulatory at Agenus, shared on LinkedIn: "Agenus Regulatory is…

Jun 20, 2024, 15:04 | Societies

Agenus supports Fight Colorectal Cancer's webinar on navigating clinical trials

Quoting Agenus on LinkedIn: "We are proud to support Fight Colorectal Cancer’s latest webinar. Tune…

Jun 18, 2024, 23:25 | Insight

The future of immuno-oncology discussion with Agenus at ESMO GI 2024

Agenus shared a post on LinkedIn: “Are you a physician attending ESMO GI 24? Join…

Jun 15, 2024, 02:09 | Insight

Anthony El-Khoueiry: Botensilimab with expansion in MSS CRC; activity noted across multiple cold tumors

Anthony El-Khoueiry, Associate Professor of Medicine at University of Southern California Norris Comprehensive Cancer Center,…

Jun 13, 2024, 23:58 | Insight

Steven O'Day shared the latest data and insights from our botensilimab programs - Agenus

Agenus shared on LinkedIn: "Yesterday, our Chief Medical Officer, Dr. Steven O'Day, joined clinical experts…

Jun 13, 2024, 17:33 | Insight

Agenus' Phase 1 clinical trial results have been published in Nature

Agenus shared their publication on investigational immunotherapeutic agents in Nature: "Results from our Phase 1…

Jun 12, 2024, 03:29 | Blog

Agenus is participating in the Goldman Sachs 45th Annual Global Healthcare Conference

Agenus shared on LinkedIn: “Tomorrow, Agenus is participating in the Goldman Sachs 45th Annual Global Healthcare…

Jun 10, 2024, 16:17 | Blog

Steven O’Day will be presenting an update on botensilimab programs at Nature Conferences’s event - Agenus

Quoting Agenus on X: "Tomorrow, Dr. Steven O’Day will be speaking at Nature Conferences’ Cancer Immunotherapy…

Jun 9, 2024, 08:12 | Blog

Gevorg Tamamyan: The Yvonne Award received a warm welcome from the international professional community

Gevorg Tamamyan shared on LinkedIn: "Last Friday, on May 31, the OncoDaily Party and Yvonne Awards Ceremony…

Jun 7, 2024, 11:02 | Career

Robin Taylor: Wonderful to have Eric Olson bringing his extensive Regulatory experience to Agenus

Robin Taylor, Chief Commercial Officer at Agenus, recently shared a post by Eric Olson, former…

Jun 4, 2024, 10:34 | Blog

Congratulations to Dr. Pashtoon Kasi on receiving the Yvonne Award from OncoDaily - Agenus

Agenus shared on LinkedIn: "Congratulations to Dr. Pashtoon Kasi on receiving the Yvonne Award from OncoDaily…

Jun 4, 2024, 05:09 | Insight

Join us in Chicago to discuss the future of immuno-oncology - Agenus

Agenus shared a post on LinkedIn: “Are you a physician attending ASCO24? Join us in…

May 31, 2024, 23:43 | Blog

Dr. Benny Johnson shares his insights on the importance of innovative immunotherapy treatments - Agenus

Agenus shared a post on LinkedIn: "As Cancer Research Month nears a close, Dr. Benny Johnson shares…

May 30, 2024, 11:22 | Societies

A new analysis of bot/bal in metastatic MSS colorectal cancer at ASCO24 - Agenus

Agenus recently shared a post on LinkedIn: "Agenus is headed to ASCO24 where Dr. Marwan…

May 23, 2024, 09:37 | Blog

Agenus: We’re proud to share Dr. Joseph Grossman’s perspective of our investigational immunotherapy pipeline

Agenus shared a post on LinkedIn: "At Agenus, we aim to transform care for individuals living…

May 17, 2024, 11:18 | Drugs

Agenus has been granted a Type B End-of-Phase 2 meeting from the U.S. FDA

Agenus shared on LinkedIn: “Today we announced that Agenus has been granted a Type B…

May 13, 2024, 07:25 | Blog

Partnership between Ligand Pharmaceuticals and Agenus

Ligand Pharmaceuticals shared on their LinkedIn page: "We are excited to announce our latest royalty…

May 12, 2024, 03:08 | Blog

CEO of Agenus, Garo Armen shares details on our royalty financing agreement with Ligand Pharmaceuticals

Agenus shared on LinkedIn: “‘With this infusion of capital, we are poised to accelerate the…

May 9, 2024, 12:46 | Blog

Zack Armen: A major transaction with Ligand Pharmaceuticals and Agenus

Zack Armen, Head of Investor Relations at Agenus, shared a post on LinkedIn: ''Yesterday we…

Apr 13, 2024, 15:16 | Blog

Zack Armen: This is incredibly exciting for patients with neoadjuvant colon and rectal cancer

Zack Armen, Head of Investor Relations at Agenus, shared a post by Pashtoon Kasi, Oncologist…

Apr 13, 2024, 06:43 | Opinion

Agenus announced updated Phase 1 data and progress botensilimab/balstilimab combination in metastatic MSS colorectal cancer

Agenus shared on LinkedIn: "Today we announced updated Phase 1 data and progress on our investigational…

Apr 9, 2024, 15:56 | Blog

We’ve been energized and inspired by our time at AACR2024 - Agenus

Agenus shared a post on LinkedIn: “We’ve been energized and inspired by our time at AACR2024.…

Apr 9, 2024, 09:15 | Blog

Nicholas Skiadas: Today I get my first dose of Botensilimab/Balstilimab

Nicholas Skiadas, Cardiologist in Jacksonville, Florida, shared a post on X: "Hopefully we are headed…

Mar 31, 2024, 23:33 | Blog

Steven O'Day: Please take one lesson with you as Colorectal Cancer Awareness Month nears it ends - get screened!

Steven O'Day shared a post on LinkedIn: "Please take one lesson with you as Colorectal Cancer…

Mar 30, 2024, 14:29 | Career

Melissa Orilall Gets Promoted to Executive Director of Global Financial Operations at Agenus

Melissa Orilall shared on LinkedIn: "I’m happy to share that I’m starting a new position…

Mar 30, 2024, 14:12 | Blog

Jennifer Buell: I ride in the Pan Mass Challenge to eliminate the premature loss of so many important lives, to stand with our fighters, to illuminate hope

Jennifer Buell, the President and Chief Executive Officer of MiNK Therapeutics, shared on LinkedIn: "I…

Mar 28, 2024, 15:32 | Career

Claire Nolan Takes on Managerial Role at Agenus responsible for the Global Events and Special Projects

Claire Nolan, shared on LinkedIn: "I’m happy to share that I’m starting a new position…

Mar 10, 2024, 16:44 | Blog

Steven O’Day: March is Colorectal Cancer Awareness Month—a time where I am reminded of the resilience and courage of those affected by this disease

Steven O’Day shared on LinkedIn: "March is Colorectal Cancer Awareness Month—a time where I am…

Mar 5, 2024, 20:08 | Blog

Agenus joins the colorectal cancer community around the globe to bring attention and raise awareness on the second leading cause of cancer death in the United States - Agenus

Mar 3, 2024, 05:48 | Blog

Check out the latest 'Ask the Expert' webinar hosted by Melanoma Research Foundation - Agenus

Agenus shared a post on LinkedIn: ''In case you missed it, check out the latest…

Feb 22, 2024, 17:59 | Blog

“The Immuno-Oncology Curve” with Dr. Steven O'Day – Guests are Dr. Joseph Grossman and Dr. Benny Johnson

Steven O'Day, the Chief Medical Officer of Agenus, shared on LinkedIn: "In the latest episode…

Feb 14, 2024, 14:59 | Blog

Yelena Janjigian is leading the investigator-initiated trial of the First Novel Combination of MiNK's Allogeneic Cell Therapy with Agenus' BOT/BAL

Today MiNK Therapeutics released an announcement of the First Refractory Gastric Cancer Patient Dosed in…

Feb 14, 2024, 13:40 | Insight

Karen Bedirian: Happy to share that IMMONC received regulatory approval to conduct a trial of BAL+BOT among patients with metastatic non-small cell lung cancer

Karen Bedirian, Projects Director at Immune Oncology Research Institute, shared on LinkedIn: "Happy to share…

Jan 27, 2024, 15:39 | Blog

Agenus joined oncology leaders from across the globe at ASCO GI (GI24)

Agenus recently posted on their LinkedIn page: "Agenus joined oncology leaders from across the globe…

Dec 13, 2023, 17:13 | Blog

Angela V. Hafner: Agenus to Receive $25 Million from Bristol Myers Squibb

Angela V. Hafner, Associate Director, External Innovation at Agenus, made the following post on LinkedIn:…